RecruitingNot ApplicableNCT06362902
Laparoscopic Right Hemicolectomy With Transrectal Specimen Extraction for Colon Cancer
Sponsor
National Cancer Center, China
Enrollment
37 participants
Start Date
Mar 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the preliminary surgical outcomes of laparoscopic right hemicolectomy with transrectal specimen extraction. The hypothesis is that this type of natural orifice specimen extraction surgery (NOSES) could achieve good short-term and oncological outcomes for right colon cancer patients.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Biopsy proven colon carcinoma;
- Imaging diagnosis of T1-3 colon cancer;
- The tumor located in the cecum, ascending colon, or colonic hepatic flexure;
- Maximal tumor diameter ≤5 cm;
- Body mass index (BMI) ≤30 kg/m2;
- Written informed consent;
Exclusion Criteria6
- Complete intestinal obstruction;
- Hepatitis activity and peripheral neuropathy (such as peripheral neuritis, pseudo meningitis, motor neuritis, and sensory impairment);
- Significant organ dysfunction or other significant diseases, including clinically relevant coronary artery disease, cardiovascular disease, or myocardial infarction within the 12 months before enrollment; severe neurological or psychiatric history; severe infection; active disseminated intravascular coagulation;
- Pregnancy or breastfeeding;
- Alcohol abuse or drug addiction;
- Concurrent uncontrolled medical condition;
Interventions
PROCEDURELaparoscopic right hemicolectomy with transrectal specimen extraction
Laparoscopic right hemicolectomy with transrectal specimen extraction
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06362902
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
NCT068029912 locations
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT058069319 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations